Biphenylindanone A

From Self-sufficiency
Revision as of 19:05, 20 July 2010 by 131.173.17.182 (Talk)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Biphenylindanone A
220px
Systematic (IUPAC) name
3’-(((2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydro- 1H-inden-5-yl)oxy)methyl)biphenyl-4-carboxylic acid
Identifiers
ATC code none
PubChem CID 9868580
Chemical data
Formula C30H30O4
Molar mass 454.556 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Biphenylindanone A (BINA, LS-193,571) is a research agent which acts as a potent and selective positive allosteric modulator for the group II metabotropic glutamate receptor subtype mGluR2.

In animal studies it showed anxiolytic and antipsychotic effects,[1] and blocked the effects produced by the hallucinogenic drug DOB. BINA and other selective mGluR2 positive modulators have therefore been suggested as a novel class of drugs for the treatment of schizophrenia which may have superior properties to traditional antipsychotic drugs.[2]

BINA decreases cocaine self-administration in rats, with no effect on food self-administration, and is in regard to this discrimination superior to the mGluR2/3 agonist LY-379,268[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Galici R, Jones CK, Hemstapat K; et al. (2006). "Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice". The Journal of pharmacology and experimental therapeutics. 318 (1): 173–85. doi:10.1124/jpet.106.102046. PMID 16608916. 
  2. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E (2007). "A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis". Molecular pharmacology. 72 (2): 477–84. doi:10.1124/mol.107.035170. PMID 17526600. 
  3. PMID 20555310